Loomis, Sayles & Company
AMRI

Loomis, Sayles & Company’s Albany Molecular Research Inc AMRI Stock Holding History

Loomis, Sayles & Company’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-120,746
Closed -$2.62M – 1018
2017
Q2 		$2.62M Sell
120,746
-519,285
-81% -$9.42M 0.01% 541
2017
Q1 		$8.98M Sell
640,031
-14,817
-2% -$243K 0.02% 435
2016
Q4 		$12.3M Sell
654,848
-3,284
-0.5% -$55.8K 0.03% 388
2016
Q3 		$10.9M Buy
658,132
+19,465
+3% +$288K 0.03% 408
2016
Q2 		$8.58M Buy
638,667
+575,543
+912% +$8.4M 0.02% 438
2016
Q1 		$965K Buy
+63,124
New +$989K ﹤0.01% 579

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Loomis, Sayles & Company's AMRI Position: Q3 2017 in Review

Loomis, Sayles & Company sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 120,746 shares — an estimated $2.62M sold.

Loomis, Sayles & Company first reported a position in AMRI in Q1 2016 and held it in 6 quarters. The position peaked at $12.3M in Q4 2016. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Loomis, Sayles & Company reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Loomis, Sayles & Company sold 120,746 Albany Molecular Research Inc shares in Q3 2017, an estimated $2.62M.
  • Loomis, Sayles & Company first reported a position in Albany Molecular Research Inc in Q1 2016 and held it in 6 quarters.
  • Loomis, Sayles & Company's Albany Molecular Research Inc position peaked at $12.3M in Q4 2016.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Loomis, Sayles & Company's 13F filing for Q3 2017, filed 14 Nov 2017.